{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:12:31Z","timestamp":1785247951173,"version":"3.55.0"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>CFTR modulators are a class of medications prescribed to people with cystic fibrosis (pwCF) who have certain genetic mutations. In 2019, elexacaftor\/tezacaftor\/ivacaftor (ETI) was approved by the FDA and led to significant health improvements for pwCF. Despite ETI showing significant health improvements compared to prior modulators, little is known about how ETI impacts the lived experience of pwCF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study explored how the implementation of ETI in cystic fibrosis treatment has impacted the lived experience of pwCF and what additional resources healthcare providers should be offering to their patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We conducted a qualitative study that recruited pwCF from an adult CF center who were over the age of 18 and had been on ETI for at least a year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted and recorded semi-structured interviews with participants over the Zoom platform. Dedoose was used to code the data and themes were constructed using inductive coding rooted in grounded theory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Four themes were constructed from the data in this study: (1) \u201ctransformation in health\u201d refers to the change in physical health the participants have noticed since starting ETI, (2) \u201cfuture planning and opportunities\u201d highlights new opportunities becoming available and a new desire to plan for the future, (3) \u201cimpact on relationships\u201d describes how participants felt their relationships with their partner, family, and care teams, were impacted by ETI, (4)\u201cnew worries and struggles\u201d describes new struggles and concerns that participants have faced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The data from this study provide evidence that ETI has not only impacted pwCF on a physical level, but may also have an impact on relationships, mental health, and future planning. It also highlights the need for additional resources that CF care teams should be providing to their patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666261469021","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:09:16Z","timestamp":1784970556000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor\/tezacaftor\/ivacaftor for treatment"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5448-1213","authenticated-orcid":false,"given":"Alyssa","family":"Riggle","sequence":"first","affiliation":[{"name":"School of Medicine, Case Western Reserve University, Cleveland, OH 44106-4915, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Page","sequence":"additional","affiliation":[{"name":"TriHealth Precision Medicine Institute, Montgomery, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Roesch","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonology, University Hospitals Rainbow Babies and Children\u2019s Hospital, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Michie","sequence":"additional","affiliation":[{"name":"Department of Bioethics, Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Darrah","sequence":"additional","affiliation":[{"name":"Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15155"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26412"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.03.003"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1193-9"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2017.04.010"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-012-9555-1"},{"key":"e_1_3_5_9_2","article-title":"Lingering identity as chronically ill and the unanticipated effects of life-changing precision medicine in cystic fibrosis: a case report","volume":"8","author":"Ladores S","year":"2021","unstructured":"Ladores S, Polen M. Lingering identity as chronically ill and the unanticipated effects of life-changing precision medicine in cystic fibrosis: a case report. J Patient Exp 2021; 8: 2374373521996971.","journal-title":"J Patient Exp"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/17423953221099042"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01825-2"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030410"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.11.008"},{"key":"e_1_3_5_15_2","article-title":"Psychological wellbeing post Elexacaftor-Tezacaftor-Ivacaftor (ETI) treatment in cystic fibrosis","author":"Keyte R","unstructured":"Keyte R, Egan H. Psychological wellbeing post Elexacaftor-Tezacaftor-Ivacaftor (ETI) treatment in cystic fibrosis. Psychol Health Med. Epub ahead of print 24 November 2025.","journal-title":"Psychol Health Med"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2524.2006.00619.x"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.12.008"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050312118822927"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26527"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2020.07.009"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261469021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666261469021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261469021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:48:07Z","timestamp":1785246487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666261469021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"alternative-id":["10.1177\/17534666261469021"],"URL":"https:\/\/doi.org\/10.1177\/17534666261469021","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666261469021\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261469021\/v2\/review1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17534666261469021"}}